Q32 Bio (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$5.85
-$0.23(-6.52%)
At close: 4:00 PM EST
$5.85
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $8.05
Previous CloseN/A
Volume113.57K
Average Volume (3M)339.19K
Market Cap
$81.92M
Enterprise Value$30.53M
Total Cash (Recent Filing)$48.30M
Total Debt (Recent Filing)$11.18M
Price to Earnings (P/E)0.2
Beta0.39
Next Earnings
May 07, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.58
Shares Outstanding14,629,463
10 Day Avg. Volume272,731
30 Day Avg. Volume339,189
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit0.57
Enterprise Value/Ebitda1.60
Forecast
1Y Price Target
$14.33Price Target Upside145.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Biologics PipelineQ32 Bio’s focus on monoclonal antibody programs across discovery through clinical trials is a durable business foundation. Biologics targeting immune pathways benefit from high technical barriers, established commercial pathways, and potential long-term value if programs translate, supporting strategic optionality over months.
Expanded Equity Financing CapacityThe enlarged ATM/shelf capacity materially improves financing flexibility, a structural benefit for a cash-burning clinical-stage biotech. Reliable access to equity capital reduces near-term funding risk for clinical programs and extends runway to progress trials without immediate asset sales or partnerships.
Balance Sheet RepairThe materially improved capital structure—lower debt and much higher equity—reduces leverage and interest burden, improving financial flexibility. This repair lessens insolvency risk and provides a stronger base to fund R&D over the medium term compared with prior years of negative equity.
Bears Say
Lack Of Recurring RevenueWith effectively no recurring revenue, Q32 lacks a sustainable operating cash base; commercialization and customer-derived cash flows are not established. This structural absence forces dependence on capital markets and makes long-term planning and margin visibility highly uncertain until product revenues materialize.
Persistent Negative Cash FlowChronic operating cash deficits mean the company must continually access external funding to support R&D and trials. Although burn improved in 2025, ongoing negative free cash flow structurally elevates dilution risk and constrains strategic choices until cash generation turns positive or funding becomes repeatedly available.
Questionable Earnings QualityThe 2025 profitability swing appears driven by non-operational items rather than sustainable operations, reducing the reliability of reported earnings. This undermines confidence in margin sustainability and complicates forecasting, since reported profits do not reflect repeatable commercial success.
Q32 Bio News
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.34 and its highest was $8.04 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $81.92M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is May 07, 2026 which is in 5 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Mar 10, 2026. The company reported $4.58 earnings per share for the quarter, beating the consensus estimate of -$0.86 by $5.44.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -0.68.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 14,629,463 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of $4.58 in its last earnings report, beating expectations of -$0.86. Following the earnings report the stock price went up 17.451%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.33 (145.01% Upside)
$14.33 (145.01% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $75.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
175.94%
12-Months-Change
Fundamentals
Return on Equity
1630.23%
Trailing 12-Months
Asset Growth
-33.09%
Trailing 12-Months
Company Description
Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
QTTB Stock 12 Month Forecast
Average Price Target
$14.33
▲(145.01% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
3.06% Insiders
2.77% Mutual Funds
48.61% Other Institutional Investors
42.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---